Tarsus Pharmaceuticals, Inc. Common Stock

TARSNASDAQ

Healthcare · Biological Products, (no Diagnostic Substances)

Market cap

$2.58B

Employees

370

Exchange

NASDAQ

Headquarters

IRVINE, CA

About Tarsus Pharmaceuticals, Inc. Common Stock

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Industry

Biological Products, (no Diagnostic Substances)

Sector

Healthcare

Country

US

Website

www.tarsusrx.com